AzTrials
AzTrials

Oesophageal CancerNCT06965205

Use of Different Enteral Feeds to Impact on Chyle Leaks in Oesophagectomy

A study testing MCT feeding and Standard feeds in people with Oesophageal Cancer, run by Royal College of Surgeons, Ireland.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record
Search all trials

Trial summary

Oesophagectomy (surgery to remove a cancerous portion of the oesophagus or gullet) is the cornerstone of treating oesophageal cancer. In recent years, minimally invasive techniques, including robotic assisted oesophagectomy have been introduced. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Oesophageal Cancer
What is being tested?
MCT feeding and Standard feeds
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
160 participants
Where
No sites listed yet
Study dates
5 May 2025to 31 Dec 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All adults aged over 18 years undergoing MIO or RAMIO for oesophageal cancer (adenocarcinoma and squamous cell cancer) at Beaumont Hospital will be approached for inclusion.

Who cannot join

  • Patients will be excluded if
  • They are unable to provide informed consent
  • They do not receive a feeding jejunostomy at or prior to their oesophagectomy
  • Prior or concomitant malignancy that would interfere with this protocol

About this study

Official title: Impact of Enteral Feeding Approaches on Chyle Leaks in Oesophageal Cancer Surgery

Oesophagectomy (surgery to remove a cancerous portion of the oesophagus or gullet) is the cornerstone of treating oesophageal cancer. In recent years, minimally invasive techniques, including robotic assisted oesophagectomy have been introduced. These techniques reduce stress on patients, reduce pain, reduce the length of stay in hospital after their operation, without compromising cancer outcomes (and in some cases improving cancer outcomes). Any surgery carries the risk of complications. One complication that may arise with oesophagectomy is an increase in chyle leaks. Chyle is a fluid produced by the body that helps transport nutrients from the bowel to the bloodstream to allow them to be absorbed and processed. One of the channels that transports chyle, the thoracic duct, is divided as part of an oesophagectomy. Although it is clipped to reduce the risk of chyle leak, this may still occur, in up to 25% of operations. If a chyle leak occurs, a drainage tube needs to remain in the chest for a number of days, there may be alterations in the use of feeding techniques, and in a small portion of cases, there may need to be an operation to stop a leak, or a procedure in the radiology department. The goal of this study is to see whether use of a different type of post-operative feed (medium chain triglyceride or MCT feeds) can reduce the rate of chyle leak. This is already used

to treat chyle leaks, and the question is whether using this as the routine post-operative feed can reduce rates of chyle leakage.

Read the detailed description

What is the purpose of the study? Oesophagectomy (surgery to remove a cancerous portion of the oesophagus or gullet) is the cornerstone of treating oesophageal cancer. In recent years, minimally invasive techniques, including robotic assisted oesophagectomy have been introduced. These techniques reduce stress on patients, reduce pain, reduce the length of stay in hospital after their operation, without compromising cancer outcomes (and in some cases improving cancer outcomes). Any surgery carries the risk of complications. One complication that may arise with oesophagectomy is an increase in chyle leaks. Chyle is a fluid produced by the body that helps transport nutrients from the bowel to the bloodstream to allow them to be absorbed and processed. One of the channels that transports chyle, the thoracic duct, is divided as part of an oesophagectomy. Although it is clipped to reduce the risk of chyle leak, this may still occur, in up to 25% of operations. If a chyle leak occurs, a drainage tube needs to remain in the chest for a number of days, there may be alterations in the use of feeding techniques, and in a small portion of cases, there may need to be an operation to stop a leak, or a procedure in the radiology department. The goal of this study is to see whether use of a different type of post-operative feed (medium chain triglyceride or MCT feeds) can reduce the rate of chyle leak. This is already used to treat chyle leaks, and the question is whether using this as the routine post-operative feed can reduce rates of chyle leakage.

What will happen during the study? The oesophagectomy will proceed as planned. As part of all minimally invasive oesophagectomies, a feeding tube will be placed into the small bowel (feeding jejunostomy). This will be used to support feeding and nutrition in the post-operative period. As standard, the investigators also place a drainage tube in the right chest to drain fluid post-operatively. If the patient is recovering well, the investigators will begin feeding on the first day post-operative day. This will either be with the currently used feed (Nutrison Protein Plus) or with the MCT feed (Nutrison Peptisorb). If progressing well, oral intake will be introduced slowly from the third post-operative day. The investigators will measure the volume of fluid draining from the post-operative drain and analyse it in the lab to determine if there is a post-operative chyle leak. Should a chyle leak occur, it will be treated as per our usual protocol, which may include using alternative jejunostomy feeds, intravenous feeding (total parenteral nutrition), a procedure in radiology, or a repeat operation. All patients will be transitioned back to standard feeds for discharge.

Currently, unless contra-indicated (eg a feeding jejunostomy has not been placed), patients post MIO/RAMIO will commence percutaneous enteral feeds on the first post-operative day using a standardized enteral feeding formulation (Nutrison Protein Plus 1.25kcal/ml at 20ml/hr for 24 hours). This is then sequentially progressed until the patient is at their goal rate to meet their caloric and nutritional requirements. If there are no contraindications, PO intake commences on the 3rd post-operative day with restricted PO fluids, followed by progressive introduction of PO intake, as per our standard post-operative protocols.

Our hypothesis is, that by switching the enteral feed from standard feed to an MCT feed, this will reduce the production of chyle, allowing lymphatics to seal, and reduce the incidence of chylothorax post MIO/RAMIO.

This is a prospective randomized controlled trial. The sample size is 148 patients (72 each in intervention and control groups). The principal investigators (JB and WR) will be blinded to which feed patients are receiving. Due to the practicalities of administering jejunostomy feeds, the clinical dietetics service, nursing service and the non-consultant medical staff will not be blinded to the interventions. Due to the need to instigate training for home feeding, patients will not be blinded to the intervention.

Randomization will be conducted using block randomization, under the supervision of the clinical leads (from clinical dietetics and NCHD leads). Patients will be randomized in blocks of 5. This will facilitate streamlining of interventions and reduce the risk of error in dispensing the correct feeds.

The surgical approach is standardized, both for MIO and RAMIO. For Ivor Lewis (2-stage) oesophagectomy, the gastric conduit is mobilized laparoscopically or robotically, fashioning a 4cm wide gastric conduit. A standard lymphadenectomy is performed, and transhiatal dissection is undertaken, with care to widely dissect the oesophagus from the crura, pericardium and from the aorta. Dissection is undertaken with an energy device as per operating surgeon (Harmonic Scalpel, Ligasure or Vessel Sealer). A standard feeding jejunostomy tube is placed, approximately 30-60cm from the duodenal-jejunal flexure. As the pleural is resected, a wide bore (minimum 24Fr) chest drain is placed in the left pleural space. The thoracoscopic phase is undertaken in standard fashion. Peri-oesophageal lymph nodes and subcarinal nodes are resected as standard. The thoracic duct is identified and clipped or ligated proximally and distally, and a portion is resected en-block with the oesophagus. Dissection is undertaken with electrocautery or an energy device (Harmonic Scalpel, Ligasure or Vessel Sealer) as per operating surgeon. A stapled oesophagogastric anastomosis is undertaken in standard fashion, at or above the level of the azygous vein. A wide bore chest drain (at least 24Fr) is placed in the right pleural space and connected to an underwater seal to allow drainage.

The approach for a McKeown operation is similar, although the thoracic phase is the first portion of the operation, and the anastomosis is performed in the neck (usually hand-sewn).

The primary outcome is the incidence of proven chylothorax. To this end, a sample of chest drain effluent from the right chest drain will be sent for cytological and biochemical analysis on days 1, 3 and 5 post-operatively. A chyle leak will be defined as per the Esophageal Complications Consensus Group as:

  • A milky effusion >200ml in 24 hours upon initiation of enteral feeds AND/OR pleural fluid analysis demonstrating triglyceride level >100mg/dL AND/OR chylomicrons in pleural fluid (at least 2 elements present to confirm chyle leak)
  • A final definition of the severity of chyle leak is based on definitive treatment:
  • Type 1: dietary modification
  • Type 2: TPN
  • Type 3: Interventional radiology or surgery
  • Each is subdivided into A) or B) based on volume of effusion at commencement of treatment (A is <1L/24h, B is >1L/24h)

If a chyle leak is established, treatment will be at the discretion of the responsible surgeon and clinical team.

For secondary outcomes

  • The volume of chest drain effluent is recorded on a daily basis
  • Re-intervention (IR or surgical) will be recorded
  • LOS will be recorded
  • All other complications will be recorded according to ECCG definitions and will be graded using the Clavien Dindo system.

Following recruitment, patients will be randomized to receive standard jejunostomy feeds, or MCT feeds. Standard feeds will be with Nutrison Protein Plus 1.25kcal/ml. MCT feeds will be initiated using Nutrison Peptisorb 1kcal/ml. Peptisorb has lower fat content, with a higher proportion of MCTs. The feeding protocol for both formulae will be the same, with equivalent rates of enteral feeding:

  • Day 1: if no clinical contra-indication, commence feeding either with standard or MCT feeds at 20ml/hr for 24 hours. Feeds to commence at 8am.
  • Day 2: if tolerating feeds continue feeds at 20ml/hr for 12 hours, then increase to 40ml/hr for 12 hours
  • Day 3: if tolerating feeds increase feeds to 60ml/hr and await dietician review regarding target rate and duration.

By POD6, if there is no chyle leak, all patients will be given standard feeds for discharge home.

For oral feeding, if patients are progressing clinically, they will have restricted fluids on POD3, with introduction of diet in each group from day 4 onwards. This allows a direct comparison of chyle leak rates for 72h of regular vs MCT enteral feeding.

Being tested
MCT feeding, Standard feeds
Keywords
Oesophageal cancer, chyle leak, MCT feed
Medical subject headings
Esophageal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MCT feedingDietary supplement

    MCT feeds will be initiated using Nutrison Peptisorb 1kcal/ml. Peptisorb has lower fat content, with a higher proportion of MCTs. The feeding protocol for both formulae will be the same, with equivalent rates of enteral feeding:

    • Day 1: if no clinical contra-indication, commence feeding either with standard or MCT feeds at 20ml/hr for 24 hours. Feeds to commence at 8am.
    • Day 2: if tolerating feeds continue feeds at 20ml/hr for 12 hours, then increase to 40ml/hr for 12 hours
    • Day 3: if tolerating feeds increase feeds to 60ml/hr and await dietician review regarding target rate and duration.

    By POD6, if there is no chyle leak, all patients will be given standard feeds for discharge home.

    For oral feeding, if patients are progressing clinically, they will have restricted fluids on POD3, with introduction of diet in each group from day 4 onwards. This allows a direct comparison of chyle leak rates for 72h of regular vs MCT enteral feeding.

  • Standard feedsDietary supplement

    Nutrison Protein Plus 1.25kcal/ml.

Study groups in NCT06965205
Study groupRoleWhat they receive
Standard feedsActive comparatorStandard feeds will be with Nutrison Protein Plus 1.25kcal/ml. * Day 1: if no clinical contra-indication, commence feeding either with standard or MCT feeds at 20ml/hr for 24 hours. Feeds to commence at 8am. * Day 2: if tolerating feeds continue feeds at 20ml/hr for 12 hours, then increase to 40ml/hr for 12 hours * Day 3: if tolerating feeds increase feeds to 60ml/hr and await dietician review regarding target rate and duration. For oral feeding, if patients are progressing clinically, they will have restricted fluids on POD3, with introduction of diet in each group from day 4 onwards. This allows a direct comparison of chyle leak rates for 72h of regular vs MCT enteral feeding.
Receives: Dietary Supplement: Standard feeds
MCT feedsExperimentalMCT feeds will be initiated using Nutrison Peptisorb 1kcal/ml. Peptisorb has lower fat content, with a higher proportion of MCTs. The feeding protocol for both formulae will be the same, with equivalent rates of enteral feeding: * Day 1: if no clinical contra-indication, commence feeding either with standard or MCT feeds at 20ml/hr for 24 hours. Feeds to commence at 8am. * Day 2: if tolerating feeds continue feeds at 20ml/hr for 12 hours, then increase to 40ml/hr for 12 hours * Day 3: if tolerating feeds increase feeds to 60ml/hr and await dietician review regarding target rate and duration. By POD6, if there is no chyle leak, all patients will be given standard feeds for discharge home. For oral feeding, if patients are progressing clinically, they will have restricted fluids on POD3, with introduction of diet in each group from day 4 onwards. This allows a direct comparison of chyle leak rates for 72h of regular vs MCT enteral feeding.
Receives: Dietary Supplement: MCT feeding

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of patients with a confirmed chyle leak

    A milky effusion >200ml in 24 hours upon initiation of enteral feeds AND/OR pleural fluid analysis demonstrating triglyceride level >100mg/dL AND/OR chylomicrons in pleural fluid (at least 2 elements present to confirm chyle leak)

    Measured: Within first 5 post-operative days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 May 2025
  2. Study start5 May 2025 (estimated)
  3. Primary completion5 May 2030 (estimated)
  4. Study completion31 Dec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
160 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06965205
Sponsor's protocol ID
25/11
Status last verified
Apr 2025
First submitted
16 Apr 2025
Last updated
11 May 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: IPD used in publication

Questions about this trial

What is this clinical trial studying?

A study testing MCT feeding and Standard feeds in people with Oesophageal Cancer, run by Royal College of Surgeons, Ireland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 11 May 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of patients with a confirmed chyle leak (time frame: Within first 5 post-operative days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in